Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06649045 · ClinicalTrials.gov registry record · Phase 3
A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight
A Phase 3 study of Overweight or Obesity and OSA, sponsored by Eli Lilly and Company.
- Active
- Registry status
- Phase 3
- Development phase
- 600
- Enrollment target
- 20
- Study locations
NCT06649045: Active Phase 3 study of Overweight or Obesity and OSA, sponsored by Eli Lilly and Company.
NCT06649045 is a Phase 3 study of Overweight or Obesity and OSA that is active but no longer recruiting, run by Eli Lilly and Company. The registered enrollment target is 600 participants, below the 31,694-participant average among 32 other Overweight or Obesity trials with a reported enrollment target (98% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06649045, a Phase 3 study of Overweight or Obesity and OSA, is active but no longer recruiting, sponsored by Eli Lilly and Company.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 600 participants
- Enrollment target
- 20
- Study locations
Study Summary
Study GZRA is a master protocol that will support 2 independent studies, GZ01 and GZ02. Participants will be assigned to the appropriate study prior to randomization. The purpose of the studies is to evaluate the efficacy and safety of orforglipron in participants who have moderate-to-severe OSA and obesity or overweight. Study GZ01 will include participants who are unable or are unwilling to use PAP therapy. Study GZ02 will include participants who are on PAP therapy for at least 3 months at time of screening and plan to continue PAP therapy during the study.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Orforglipron
Study Locations (20)
Other
- Centro de Investigaciones Metabólicas (CINME) - Buenos Aires
- Centro Médico Viamonte - Buenos Aires
- Consultorio de Investigación Clínica EMO SRL - Buenos Aires
- Centro Medico Dra. Laura Maffei- Investigacion Clinica Aplicada - Buenos Aires
- Centro Privado de Medicina Respiratoria - Paraná
California
- Ark Clinical Research - Long Beach
- Peninsula Research Associates - Rolling Hills Estates
- Artemis Institute for Clinical Research - San Diego
Pennsylvania
- Preferred Primary Care Physicians, Preferred Clinical Research (Ofc 18) - Pittsburgh
- Preferred Primary Care Physicians - Uniontown
Texas
- FutureSearch Trials of Neurology - Austin
- Prime Revival Research Institute, LLC - Flower Mound
Colorado
- Care Access - Aurora - Aurora
Georgia
- EBGS Clinical Research Center - Snellville
Idaho
- Elite Clinical Trials - Blackfoot
Louisiana
- Care Access - Shreveport - Shreveport
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 600 participants |
| Start Date | 2024-10-22 |
| Est. Completion | 2027-01 |
| Phase | Phase 3 |
What the registry record for NCT06649045 still lists
NCT06649045 is an interventional study that assigns participants to a tested intervention. The registered 600 participants enrollment target is mid-sized for trials with a published cap, below the 31,694-participant average among 32 other Overweight or Obesity trials with a reported enrollment target (98% lower).
The record links to 2 conditions, with Overweight or Obesity appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06649045 names 20 study sites across 12 states, led by Other, California, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06649045 about?
NCT06649045 is a clinical study titled "A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight". Study GZRA is a master protocol that will support 2 independent studies, GZ01 and GZ02. Participants will be assigned to the appropriate study prior to randomization. The purpose of the studies is to evaluate the efficacy and safety of orforglipron in participants who have moderate-to-severe OSA and...
What is the current status of trial NCT06649045?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 600 participants. The study started on 2024-10-22. Estimated completion is 2027-01.
What conditions does trial NCT06649045 study?
This clinical trial studies the following conditions: Overweight or Obesity, OSA.
What interventions are being tested in trial NCT06649045?
The interventions under investigation include: Placebo (DRUG), Orforglipron (DRUG).
Who is sponsoring clinical trial NCT06649045?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06649045 being conducted?
This trial has 20 study locations across California, Colorado, Georgia, Idaho, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Overweight or Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06649045's enrollment target sits among peer trials
600 7th of 32 higher than 26 of 32 other Overweight or Obesity trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Overweight or Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
RECRUITING · Phase 3
-
Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation
RECRUITING · Phase 3
-
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1
RECRUITING · Phase 3
-
A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk
ACTIVE NOT RECRUITING · Phase 3
-
Remotely Delivered Resistance Training for Cardiometabolic Health Among Black Women
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00004317 · 600 participants · Phase 4
Pyrimethamine, Sulfadiazine, and Leucovorin in Treating Patients With Congenital Toxoplasmosis
- NCT00209235 · 600 participants · NA
Albright Hereditary Osteodystrophy: Natural History, Growth, and Cognitive/Behavioral Assessments
- NCT01473784 · 600 participants · NA
Transoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and Neck
- NCT01866371 · 600 participants
High Resolution Retinal Imaging
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI